ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2017477-82ometendo-8796Research ArticleСлучай из практикиCase ReportКлинический случай сочетания несовершенного остеогенеза и болезни ГрейвсаOsteogenesis imperfecta in combination with Graves diseasehttps://orcid.org/0000-0003-3785-0335ШереметаМарина СергеевнаSheremetaMarina S.

кандидат медицинских наук, зав отдлением

PhD

marina888@yandex.ruПигароваЕкатерина АлександровнаPigarovaEkaterina A.

кандидат медицинских наук

PhD

marina888@yandex.ruКуликоваКристина СергеевнаKulikovaKristina S.

кандидат медицинских наук

PhD

marina888@yandex.ruБеловаловаИрина МихайловнаBelovalovaIrina M.

кандидат медицинских наук

PhD

belovalova.irina@endocrincentr.ruТюльпаковАнатолий НиколаевичTyulpakovAnatoliy N.

доктор медицинских наук, профессор

ScD, Professor

marina888@yandex.ruhttps://orcid.org/0000-0002-7721-634XРумянцевПавел ОлеговичRumiantsevPavel O.

доктор медицинских наук

ScD

pavelrum@gmail.com<p>ФГБУ &laquo;Национальный медицинский исследовательский центр эндокринологии&raquo; Минздрава России</p>Россия<p>Endocrinology Research Centre</p>Russian Federation2017271220171447782Copyright &#x00A9; Шеремета М.С., Пигарова Е.А., Куликова К.С., Беловалова И.М., Тюльпаков А.Н., Румянцев П.О., 20172017Шеремета М.С., Пигарова Е.А., Куликова К.С., Беловалова И.М., Тюльпаков А.Н., Румянцев П.О.Sheremeta M.S., Pigarova E.A., Kulikova K.S., Belovalova I.M., Tyulpakov A.N., Rumiantsev P.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/8796

Несовершенный остеогенез (НО) – это группа генетически обусловленных заболеваний, в основе которых лежит нарушение формирования костной ткани. В свою очередь, избыток тиреоидных гормонов при болезни Грейвса (БГ) оказывает негативное влияние на костную ткань, тем самым усугубляя течение НО, что требует от эндокринолога максимально внимательного ведения пациентов с сочетанием данных патологий. В настоящей статье представлен уникальный клинический случай сочетания БГ и НО.

Osteogenesis imperfecta (OI) – is a group of genetically disorders, which are charaterized by a disturbed bone formation. In turn, the excess of thyroid hormones in Graves' disease (GD) also posses a negative effect on bone tissue, thereby aggravating OI. That requires from the endocrinologist the most careful management of patients with the combination of these pathologies. In this article, we present a unique clinical case of a combination of GD and OI.

болезнь Грейвсанесовершенный остеогенезклинический случайGraves diseaseosteogenesis imperfectaclinical caseReferencesBassett JHD, Williams GR. Role of Thyroid Hormones in Skeletal Development and Bone Maintenance. Endocr Rev. 2016;37(2):135-187. doi: 10.1210/er.2015-1106.Bassett JHD, Williams GR. Role of Thyroid Hormones in Skeletal Development and Bone Maintenance. Endocr Rev. 2016;37(2):135-187. doi: 10.1210/er.2015-1106.Lee HJ, Li CW, Hammerstad SS, et al. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J Autoimmun. 2015;64:82-90. doi: 10.1016/j.jaut.2015.07.009.Lee HJ, Li CW, Hammerstad SS, et al. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J Autoimmun. 2015;64:82-90. doi: 10.1016/j.jaut.2015.07.009.Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Reviews in Endocrine and Metabolic Disorders. 2016;17(4):485-498. doi: 10.1007/s11154-016-9363-2.Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Reviews in Endocrine and Metabolic Disorders. 2016;17(4):485-498. doi: 10.1007/s11154-016-9363-2.Chu M-L, Williams CJ, Pepe G, et al. Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta. Nature. 1983;304(5921):78-80. doi: 10.1038/304078a0.Chu M-L, Williams CJ, Pepe G, et al. Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta. Nature. 1983;304(5921):78-80. doi: 10.1038/304078a0.Le.ac.uk [Internet]. Osteogenesisimperfecta& Ehlers-Danlos syndrome variant databases [updated 2017Jun27; cited 2017Jun27]. Available from: http://www.le.ac.uk/ge/collagen/Le.ac.uk [Internet]. Osteogenesisimperfecta& Ehlers-Danlos syndrome variant databases [updated 2017Jun27; cited 2017Jun27]. Available from: http://www.le.ac.uk/ge/collagen/Willing MC, Deschenes SP, Slayton RL, Roberts EJ. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet. 1996;59(4):799-809.Willing MC, Deschenes SP, Slayton RL, Roberts EJ. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet. 1996;59(4):799-809.Cropp GJ, Myers DN. Physiological evidence of hypermetabolism in osteogenesisimperfecta. Pediatrics. 1972;49(3):375-391.Cropp GJ, Myers DN. Physiological evidence of hypermetabolism in osteogenesisimperfecta. Pediatrics. 1972;49(3):375-391.Diegidio P, Kolok D, Brown W, Camps JI. Papillary thyroid cancer in identical adolescent twins with osteogenesis imperfecta and Hashimoto's thyroiditis: is there a genetic link?Am Surg. 2014;80(9):849-850.Diegidio P, Kolok D, Brown W, Camps JI. Papillary thyroid cancer in identical adolescent twins with osteogenesis imperfecta and Hashimoto's thyroiditis: is there a genetic link?Am Surg. 2014;80(9):849-850.Chen K, Xie Y, Zhao L, Mo Z. Hyperthyroidism-associated hypercalcemic crisis: A case report and review of the literature. Medicine (Baltimore). 2017;96(4):e6017. doi: 10.1097/MD.0000000000006017.Chen K, Xie Y, Zhao L, Mo Z. Hyperthyroidism-associated hypercalcemic crisis: A case report and review of the literature. Medicine (Baltimore). 2017;96(4):e6017. doi: 10.1097/MD.0000000000006017.Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. J Endocrinol. 2012;213(3):209-221. doi: 10.1530/JOE-12-0059.Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. J Endocrinol. 2012;213(3):209-221. doi: 10.1530/JOE-12-0059.Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24-32..Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24-32..McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med. 2006;354(8):821-831. doi: 10.1056/NEJMoa044459.McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med. 2006;354(8):821-831. doi: 10.1056/NEJMoa044459.Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. Journal of Multidisciplinary Healthcare. 2017;Volume 10:145-155. doi: 10.2147/jmdh.s113483.Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. Journal of Multidisciplinary Healthcare. 2017;Volume 10:145-155. doi: 10.2147/jmdh.s113483.Hoyer-Kuhn H, Semler O, Schoenau E. Effect of Denosumab on the Growing Skeleton in Osteogenesis Imperfecta. J Clin Endocr Metab. 2014;99(11):3954-3955. doi: 10.1210/jc.2014-3072.Hoyer-Kuhn H, Semler O, Schoenau E. Effect of Denosumab on the Growing Skeleton in Osteogenesis Imperfecta. J Clin Endocr Metab. 2014;99(11):3954-3955. doi: 10.1210/jc.2014-3072.

The authors declare that there are no conflicts of interest present.